Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An evaluation of olaparib for the treatment of pancreatic cancer.

Expert opinion on pharmacotherapy - 1 Mar 2021

Vaishampayan Ulka N

Abstract excerpt

INTRODUCTION: Advanced pancreatic cancer remains a lethal, incurable malignancy. Chemotherapy is the mainstay of systemic therapy consideration in metastatic pancreas cancer. Homologous recombinant DNA repair mutations are reported in about 7% of pancreas cancer cases and have rapidly emerged as actionable mutations. AREAS COVERED: A review was conducted of publications of PARP inhibitors in pancreatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein
Share to Pancreatic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Progression-Free Survival

Share to Quality of Life

Source

Identifiers

PMID: 33094666
DOI: 10.1080/14656566.2020.1837113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An evaluation of olaparib for the treatment of pancreatic cancer.PMID 33094666Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?Semantic proximity Read ↗

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

BRCA mutations in pancreatic cancer and progress in their targeting.Semantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

BRCA mutated pancreatic cancer: A change is coming.Semantic proximity Read ↗

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancerSemantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.